IODINE I 124 GIRENTUXIMAB
drug drugOn this page
Also known as 124ICG250Girentuximab i-124Girentuximab iodine-124Iodine (124i) girentuximabRedectanecG250 (124I)
Summary
Iodine I 124 Girentuximab (CHEMBL2108713) is a phase-3 clinical-stage antibody.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Clinical trials: 2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108713 |
| Name | IODINE I 124 GIRENTUXIMAB |
| Type | Antibody |
| Max phase | 3 |
Also known as: 124ICG250, Girentuximab i-124, Girentuximab iodine-124, Iodine (124i) girentuximab, Iodine i 124 girentuximab, Redectane, cG250 (124I), IODINE I 124 GIRENTUXIMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.
Clinical trials
Total trials: 2.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01762592 | PHASE3 | WITHDRAWN | REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT |
| NCT01582204 | Not specified | ACTIVE_NOT_RECRUITING | Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.